Display options
Cite
Heudel P, Vilquin P, Tredan O, et al. Mechanisms of resistance to endocrine therapies for breast cancer. Horm Mol Biol Clin Investig. 2012;9(2):165-71doi: 10.1515/hmbci-2011-0001.
Heudel, P., Vilquin, P., Tredan, O., Ray-Coquard, I., Guastalla, J. P., Treilleux, I., & Bachelot, T. (2012). Mechanisms of resistance to endocrine therapies for breast cancer. Hormone molecular biology and clinical investigation, 9(2), 165-71. https://doi.org/10.1515/hmbci-2011-0001
Heudel, Pierre, et al. "Mechanisms of resistance to endocrine therapies for breast cancer." Hormone molecular biology and clinical investigation vol. 9,2 (2012): 165-71. doi: https://doi.org/10.1515/hmbci-2011-0001
Heudel P, Vilquin P, Tredan O, Ray-Coquard I, Guastalla JP, Treilleux I, Bachelot T. Mechanisms of resistance to endocrine therapies for breast cancer. Horm Mol Biol Clin Investig. 2012 Apr;9(2):165-71. doi: 10.1515/hmbci-2011-0001. PMID: 25436705.
Copy Download .nbib Format: NLM
Share it on

Horm Mol Biol Clin Investig. 2012 Apr;9(2):165-71. doi: 10.1515/hmbci-2011-0001.

Mechanisms of resistance to endocrine therapies for breast cancer.

Hormone molecular biology and clinical investigation

Pierre Heudel, Paul Vilquin, Olivier Tredan, Isabelle Ray-Coquard, Jean-Paul Guastalla, Isabelle Treilleux, Thomas Bachelot

PMID: 25436705 DOI: 10.1515/hmbci-2011-0001

Abstract

Abstract Breast cancer is the most frequently diagnosed cancer in women and 70% of the cases are hormone-dependent. The presence of ERα is one of the most important prognostic factors predictive of response to endocrine therapy in human breast cancers. Resistance to endocrine therapies has become a major public health concern and it appears essential to understand the mechanisms underlying this phenomenon. This review provides insights into the molecular mechanisms associated with resistance to endocrine therapies and presents the different strategies currently developed in pre-clinical models to overcome this resistance.

Publication Types